Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AmerisourceBergen names new board member
Mr Gochnauer has been president and CEO and a director of United Stationers since 2002. Mr Gochnauer has received his MBA from Harvard University and his bachelor of
Mr Gochnauer has been president and CEO and a director of United Stationers since 2002. Mr Gochnauer has received his MBA from Harvard University and his bachelor of
The company, Teva-Kowa Pharma will seek to leverage the marketing, R&D, manufacturing and distribution capabilities of each company to become a broad based supplier of high quality generic
According to the company, the Taxus Express Atom stent is a highly deliverable drug-eluting stent (DES) specifically designed for treating small coronary vessels. It is the only DES
The open label Phase II trial will enroll up to 40 patients. TLN-4601 will be continuously administered intravenously over 21-day cycles, consisting of 14 days on treatment and
Under the terms of the agreement, Merck gains worldwide rights, except for Japan, to develop and commercialize JTT-305. Japan Tobacco (JT) will receive an upfront payment and is
UCB has taken this decision based on the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) view that the magnitude of the clinical effect
The Novel cervical interbody implant is said to be the latest product in Alphatec Spine’s pipeline that provides solutions for disorders affecting the cervical spine. The Novel cervical
In this study, patients with hormone receptor expressing advanced breast therapy whose disease had progressed on an antiestrogen therapy are being randomized to treatment with either IMC-A12 as
Concert intends to evaluate CTP-347 as a non-hormonal treatment for vasomotor symptoms or hot flashes in patients with increased risk of adverse effects due to, or contraindicated to
The round, led by Nextech Venture, included additional new investors Arcus Ventures, Innovis Investments and Eli Lilly and Company. Also participating in the financing were existing investors Alexandria